Figure 4.

(A) In vivo fluorescence imaging of intracranial U251-CD133⁺ glioma tumor-bearing nude mice treated for 24 h with CLPs–PTX–survivin siRNA (B₁) or DP-CLPs–PTX–survivin siRNA (D₁) liposomes, as well as corresponding dissected organs (A₁ and C₁). (B) Lesions in nude mice implanted in situ with U251-CD133⁺ cells after treatment with CLPs–scrambled siRNA (A₁), CLPs–PTX–survivin siRNA (C₁), DP-CLPs–scrambled siRNA (B₁) or DP-CLPs–PTX–survivin siRNA (D₁); all lesions were characterized by MRI at 19 days post-injection. U251-CD133⁺ cells were intracranially implanted in nude mice after 48 h treatment with Taxol, CLPs–PTX–survivin siRNA or DP-CLPs–PTX–survivin siRNA. Tumor size was measured 19 days post-injection (n = 5/group). **p < .01 versus control, ^###p < .001 versus the CLPs–PTX–survivin siRNA group (E₁). (C) Evaluation of apoptosis in the brains of intracranial U251-CD133⁺ glioma tumor-bearing nude mice treated with CLPs–PTX–survivin siRNA (A₁–D₁) or DP-CLPs–PTX–survivin siRNA (E₁–F₁) at 48 h post-administration 2 days after intravenous administration. Images were obtained using an Annexin V-FITC Apoptosis Detection Kit. Image D₁ is the merge of images A₁, B₁ and C₁; image F₁ is the merge of E₁, F₁ and G₁. Green: apoptotic cells. Red: CD133. Blue: cell nuclei. White line: glioma border. White arrow: glioma direction. Original magnification: ×100. (D) Survival curve of U251-CD133⁺ glioma tumor-bearing nude mice.